Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: A Population-Based Cohort Study
The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the popu...
Gespeichert in:
| Veröffentlicht in: | International journal of environmental research and public health 2021-01, Vol.18 (1), p.301 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 301 |
| container_title | International journal of environmental research and public health |
| container_volume | 18 |
| creator | Wang, Kai Hsieh, Ming-Ju Chien, Hsiang-Wen Lee, Chia-Yi Yeh, Chao-Bin Huang, Jing-Yang Yang, Shun-Fa |
| description | The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the population was divided into those with fibrate application and those without via 1:2 ratios of propensity-score matching. The primary outcome is the development of AMD after dyslipidemia-related diseases by the Cox proportional hazard regression. Besides, the relationship between the medical compliance of fibrate, presented as medical possession ratio (MPR), and the AMD development was also analyzed. A total of 22,917 patients and 45,834 individuals were enrolled in the study and control groups. There were 572 and 1181 events of any AMD development in the study and control groups which showed identical risk of AMD (aHR: 0.94, 95% CI: 0.85-1.04). However, a reduced risk of any AMD was found in those patients reached a baseline MPR more than 20% (aHR: 0.729, 95% CI: 0.599-0.887,
= 0.0016) and overall MPR more than 5% three years after the diagnosis of dyslipidemia-related diseases (aHR: 0.712, 95% CI: 0.557-0.909,
= 0.0065). Besides, a lower risk of dry-AMD was also found in those patients with the above conditions (aHR: 0.736, 95% CI: 0.599-0.906,
= 0.0038 and aHR: 0.721, 95% CI: 0.557-0.934,
= 0.0133, respectively). In conclusion, the use of fibrate with fair initial medical compliance will decrease the incidence of AMD in patients with dyslipidemia-related diseases, especially for the development of dry-AMD. |
| doi_str_mv | 10.3390/ijerph18010301 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7796116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475529658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-77fbfc8599a3216455c11ed82e326636d1c39f0b34d7826c9bcf08b47096fc3f3</originalsourceid><addsrcrecordid>eNpd0UGP1CAYBuDGaNx19erRkHjx0hUKhdaDyTjjqsluNKueCYWPGUZaKrQm81f8tVJ3nex6goTne8OXtyieE3xOaYtfuz3EcUcaTDDF5EFxSjjHJeOYPLxzPymepLTHmDaMt4-LE0oZJrUQp8XvKzBOK4_WoR-9U4MGFCy6cF1UEyA1GDTtAG1AR1AJDLp26cciVlsor8FnZNCV0rNXMastDJAHXRiQG9DmkLwbnYHeqSPeuLQkpTdohb6EMQ8uvHz3N30ddiFO6Os0m8PT4pFVPsGz2_Os-H7x_tv6Y3n5-cOn9eqy1Iw0UymE7axu6rZVtCKc1bUmBExTAa04p9wQTVuLO8qMaCqu205b3HRM4JZbTS09K97e5I5z14PRMExReTlG16t4kEE5ef9lcDu5Db-kEC0nhOeAV7cBMfycIU2yd0mD92qAMCdZMVHXVcvrJtOX_9F9mOOQ11sUz4WJhmV1fqN0DClFsMfPECyX2uX92vPAi7srHPm_nukfjYirLw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476166784</pqid></control><display><type>article</type><title>Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: A Population-Based Cohort Study</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wang, Kai ; Hsieh, Ming-Ju ; Chien, Hsiang-Wen ; Lee, Chia-Yi ; Yeh, Chao-Bin ; Huang, Jing-Yang ; Yang, Shun-Fa</creator><creatorcontrib>Wang, Kai ; Hsieh, Ming-Ju ; Chien, Hsiang-Wen ; Lee, Chia-Yi ; Yeh, Chao-Bin ; Huang, Jing-Yang ; Yang, Shun-Fa</creatorcontrib><description>The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the population was divided into those with fibrate application and those without via 1:2 ratios of propensity-score matching. The primary outcome is the development of AMD after dyslipidemia-related diseases by the Cox proportional hazard regression. Besides, the relationship between the medical compliance of fibrate, presented as medical possession ratio (MPR), and the AMD development was also analyzed. A total of 22,917 patients and 45,834 individuals were enrolled in the study and control groups. There were 572 and 1181 events of any AMD development in the study and control groups which showed identical risk of AMD (aHR: 0.94, 95% CI: 0.85-1.04). However, a reduced risk of any AMD was found in those patients reached a baseline MPR more than 20% (aHR: 0.729, 95% CI: 0.599-0.887,
= 0.0016) and overall MPR more than 5% three years after the diagnosis of dyslipidemia-related diseases (aHR: 0.712, 95% CI: 0.557-0.909,
= 0.0065). Besides, a lower risk of dry-AMD was also found in those patients with the above conditions (aHR: 0.736, 95% CI: 0.599-0.906,
= 0.0038 and aHR: 0.721, 95% CI: 0.557-0.934,
= 0.0133, respectively). In conclusion, the use of fibrate with fair initial medical compliance will decrease the incidence of AMD in patients with dyslipidemia-related diseases, especially for the development of dry-AMD.</description><identifier>ISSN: 1660-4601</identifier><identifier>ISSN: 1661-7827</identifier><identifier>EISSN: 1660-4601</identifier><identifier>DOI: 10.3390/ijerph18010301</identifier><identifier>PMID: 33401577</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adult ; Age ; Aged ; Aged, 80 and over ; Atherosclerosis ; Cardiovascular disease ; Cerebrovascular disease ; Codes ; Cohort analysis ; Cohort Studies ; Compliance ; Diagnostic systems ; Diseases ; Dyslipidemia ; Dyslipidemias - complications ; Female ; Fibric Acids - therapeutic use ; Gender ; Health insurance ; Humans ; Incidence ; Lipids ; Low density lipoprotein ; Macular degeneration ; Macular Degeneration - epidemiology ; Macular Degeneration - prevention & control ; Male ; Medication Adherence - statistics & numerical data ; Medicine ; Metabolic disorders ; Middle Aged ; Morbidity ; Patients ; Population ; Population studies ; Population-based studies ; Risk Assessment ; Risk management ; Vascular endothelial growth factor ; Young Adult</subject><ispartof>International journal of environmental research and public health, 2021-01, Vol.18 (1), p.301</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-77fbfc8599a3216455c11ed82e326636d1c39f0b34d7826c9bcf08b47096fc3f3</citedby><cites>FETCH-LOGICAL-c418t-77fbfc8599a3216455c11ed82e326636d1c39f0b34d7826c9bcf08b47096fc3f3</cites><orcidid>0000-0002-5719-0488 ; 0000-0001-9726-3234 ; 0000-0002-0365-7927 ; 0000-0002-3978-5576 ; 0000-0002-0794-9388</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796116/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796116/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33401577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Kai</creatorcontrib><creatorcontrib>Hsieh, Ming-Ju</creatorcontrib><creatorcontrib>Chien, Hsiang-Wen</creatorcontrib><creatorcontrib>Lee, Chia-Yi</creatorcontrib><creatorcontrib>Yeh, Chao-Bin</creatorcontrib><creatorcontrib>Huang, Jing-Yang</creatorcontrib><creatorcontrib>Yang, Shun-Fa</creatorcontrib><title>Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: A Population-Based Cohort Study</title><title>International journal of environmental research and public health</title><addtitle>Int J Environ Res Public Health</addtitle><description>The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the population was divided into those with fibrate application and those without via 1:2 ratios of propensity-score matching. The primary outcome is the development of AMD after dyslipidemia-related diseases by the Cox proportional hazard regression. Besides, the relationship between the medical compliance of fibrate, presented as medical possession ratio (MPR), and the AMD development was also analyzed. A total of 22,917 patients and 45,834 individuals were enrolled in the study and control groups. There were 572 and 1181 events of any AMD development in the study and control groups which showed identical risk of AMD (aHR: 0.94, 95% CI: 0.85-1.04). However, a reduced risk of any AMD was found in those patients reached a baseline MPR more than 20% (aHR: 0.729, 95% CI: 0.599-0.887,
= 0.0016) and overall MPR more than 5% three years after the diagnosis of dyslipidemia-related diseases (aHR: 0.712, 95% CI: 0.557-0.909,
= 0.0065). Besides, a lower risk of dry-AMD was also found in those patients with the above conditions (aHR: 0.736, 95% CI: 0.599-0.906,
= 0.0038 and aHR: 0.721, 95% CI: 0.557-0.934,
= 0.0133, respectively). In conclusion, the use of fibrate with fair initial medical compliance will decrease the incidence of AMD in patients with dyslipidemia-related diseases, especially for the development of dry-AMD.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Atherosclerosis</subject><subject>Cardiovascular disease</subject><subject>Cerebrovascular disease</subject><subject>Codes</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Compliance</subject><subject>Diagnostic systems</subject><subject>Diseases</subject><subject>Dyslipidemia</subject><subject>Dyslipidemias - complications</subject><subject>Female</subject><subject>Fibric Acids - therapeutic use</subject><subject>Gender</subject><subject>Health insurance</subject><subject>Humans</subject><subject>Incidence</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - epidemiology</subject><subject>Macular Degeneration - prevention & control</subject><subject>Male</subject><subject>Medication Adherence - statistics & numerical data</subject><subject>Medicine</subject><subject>Metabolic disorders</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Patients</subject><subject>Population</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Risk Assessment</subject><subject>Risk management</subject><subject>Vascular endothelial growth factor</subject><subject>Young Adult</subject><issn>1660-4601</issn><issn>1661-7827</issn><issn>1660-4601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpd0UGP1CAYBuDGaNx19erRkHjx0hUKhdaDyTjjqsluNKueCYWPGUZaKrQm81f8tVJ3nex6goTne8OXtyieE3xOaYtfuz3EcUcaTDDF5EFxSjjHJeOYPLxzPymepLTHmDaMt4-LE0oZJrUQp8XvKzBOK4_WoR-9U4MGFCy6cF1UEyA1GDTtAG1AR1AJDLp26cciVlsor8FnZNCV0rNXMastDJAHXRiQG9DmkLwbnYHeqSPeuLQkpTdohb6EMQ8uvHz3N30ddiFO6Os0m8PT4pFVPsGz2_Os-H7x_tv6Y3n5-cOn9eqy1Iw0UymE7axu6rZVtCKc1bUmBExTAa04p9wQTVuLO8qMaCqu205b3HRM4JZbTS09K97e5I5z14PRMExReTlG16t4kEE5ef9lcDu5Db-kEC0nhOeAV7cBMfycIU2yd0mD92qAMCdZMVHXVcvrJtOX_9F9mOOQ11sUz4WJhmV1fqN0DClFsMfPECyX2uX92vPAi7srHPm_nukfjYirLw</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Wang, Kai</creator><creator>Hsieh, Ming-Ju</creator><creator>Chien, Hsiang-Wen</creator><creator>Lee, Chia-Yi</creator><creator>Yeh, Chao-Bin</creator><creator>Huang, Jing-Yang</creator><creator>Yang, Shun-Fa</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5719-0488</orcidid><orcidid>https://orcid.org/0000-0001-9726-3234</orcidid><orcidid>https://orcid.org/0000-0002-0365-7927</orcidid><orcidid>https://orcid.org/0000-0002-3978-5576</orcidid><orcidid>https://orcid.org/0000-0002-0794-9388</orcidid></search><sort><creationdate>20210101</creationdate><title>Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: A Population-Based Cohort Study</title><author>Wang, Kai ; Hsieh, Ming-Ju ; Chien, Hsiang-Wen ; Lee, Chia-Yi ; Yeh, Chao-Bin ; Huang, Jing-Yang ; Yang, Shun-Fa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-77fbfc8599a3216455c11ed82e326636d1c39f0b34d7826c9bcf08b47096fc3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Atherosclerosis</topic><topic>Cardiovascular disease</topic><topic>Cerebrovascular disease</topic><topic>Codes</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Compliance</topic><topic>Diagnostic systems</topic><topic>Diseases</topic><topic>Dyslipidemia</topic><topic>Dyslipidemias - complications</topic><topic>Female</topic><topic>Fibric Acids - therapeutic use</topic><topic>Gender</topic><topic>Health insurance</topic><topic>Humans</topic><topic>Incidence</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - epidemiology</topic><topic>Macular Degeneration - prevention & control</topic><topic>Male</topic><topic>Medication Adherence - statistics & numerical data</topic><topic>Medicine</topic><topic>Metabolic disorders</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Patients</topic><topic>Population</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Risk Assessment</topic><topic>Risk management</topic><topic>Vascular endothelial growth factor</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Kai</creatorcontrib><creatorcontrib>Hsieh, Ming-Ju</creatorcontrib><creatorcontrib>Chien, Hsiang-Wen</creatorcontrib><creatorcontrib>Lee, Chia-Yi</creatorcontrib><creatorcontrib>Yeh, Chao-Bin</creatorcontrib><creatorcontrib>Huang, Jing-Yang</creatorcontrib><creatorcontrib>Yang, Shun-Fa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of environmental research and public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Kai</au><au>Hsieh, Ming-Ju</au><au>Chien, Hsiang-Wen</au><au>Lee, Chia-Yi</au><au>Yeh, Chao-Bin</au><au>Huang, Jing-Yang</au><au>Yang, Shun-Fa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: A Population-Based Cohort Study</atitle><jtitle>International journal of environmental research and public health</jtitle><addtitle>Int J Environ Res Public Health</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>18</volume><issue>1</issue><spage>301</spage><pages>301-</pages><issn>1660-4601</issn><issn>1661-7827</issn><eissn>1660-4601</eissn><abstract>The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the population was divided into those with fibrate application and those without via 1:2 ratios of propensity-score matching. The primary outcome is the development of AMD after dyslipidemia-related diseases by the Cox proportional hazard regression. Besides, the relationship between the medical compliance of fibrate, presented as medical possession ratio (MPR), and the AMD development was also analyzed. A total of 22,917 patients and 45,834 individuals were enrolled in the study and control groups. There were 572 and 1181 events of any AMD development in the study and control groups which showed identical risk of AMD (aHR: 0.94, 95% CI: 0.85-1.04). However, a reduced risk of any AMD was found in those patients reached a baseline MPR more than 20% (aHR: 0.729, 95% CI: 0.599-0.887,
= 0.0016) and overall MPR more than 5% three years after the diagnosis of dyslipidemia-related diseases (aHR: 0.712, 95% CI: 0.557-0.909,
= 0.0065). Besides, a lower risk of dry-AMD was also found in those patients with the above conditions (aHR: 0.736, 95% CI: 0.599-0.906,
= 0.0038 and aHR: 0.721, 95% CI: 0.557-0.934,
= 0.0133, respectively). In conclusion, the use of fibrate with fair initial medical compliance will decrease the incidence of AMD in patients with dyslipidemia-related diseases, especially for the development of dry-AMD.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33401577</pmid><doi>10.3390/ijerph18010301</doi><orcidid>https://orcid.org/0000-0002-5719-0488</orcidid><orcidid>https://orcid.org/0000-0001-9726-3234</orcidid><orcidid>https://orcid.org/0000-0002-0365-7927</orcidid><orcidid>https://orcid.org/0000-0002-3978-5576</orcidid><orcidid>https://orcid.org/0000-0002-0794-9388</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1660-4601 |
| ispartof | International journal of environmental research and public health, 2021-01, Vol.18 (1), p.301 |
| issn | 1660-4601 1661-7827 1660-4601 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7796116 |
| source | MEDLINE; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adult Age Aged Aged, 80 and over Atherosclerosis Cardiovascular disease Cerebrovascular disease Codes Cohort analysis Cohort Studies Compliance Diagnostic systems Diseases Dyslipidemia Dyslipidemias - complications Female Fibric Acids - therapeutic use Gender Health insurance Humans Incidence Lipids Low density lipoprotein Macular degeneration Macular Degeneration - epidemiology Macular Degeneration - prevention & control Male Medication Adherence - statistics & numerical data Medicine Metabolic disorders Middle Aged Morbidity Patients Population Population studies Population-based studies Risk Assessment Risk management Vascular endothelial growth factor Young Adult |
| title | Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: A Population-Based Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A34%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20Compliance%20of%20Fibrate%20and%20the%20Decreased%20Risk%20of%20Age-Related%20Macular%20Degeneration%20in%20Dyslipidemia-Related%20Diseases:%20A%20Population-Based%20Cohort%20Study&rft.jtitle=International%20journal%20of%20environmental%20research%20and%20public%20health&rft.au=Wang,%20Kai&rft.date=2021-01-01&rft.volume=18&rft.issue=1&rft.spage=301&rft.pages=301-&rft.issn=1660-4601&rft.eissn=1660-4601&rft_id=info:doi/10.3390/ijerph18010301&rft_dat=%3Cproquest_pubme%3E2475529658%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476166784&rft_id=info:pmid/33401577&rfr_iscdi=true |